Ruria Namba, L. Young, C. Abbey, Lisa Kim, P. Damonte, A. Borowsky, J. Qi, C. Tepper, C. Macleod, R. Cardiff, J. Gregg (2006)
Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma In situClinical Cancer Research, 12
S. Courtois-Cox, Sybil Williams, Elizabeth Reczek, Bryan Johnson, Lauren McGillicuddy, Cory Johannessen, Pablo Hollstein, M. Maccollin, K. Cichowski (2006)
A negative feedback signaling network underlies oncogene-induced senescence.Cancer cell, 10 6
C. Sidman, T. Denial, J. Marshall, J. Roths (1993)
Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice.Cancer research, 53 7
A. Kennedy, J. Morton, Indrani Manoharan, D. Nelson, N. Jamieson, Jeff Pawlikowski, T. McBryan, B. Doyle, C. McKay, K. Oien, G. Enders, Rugang Zhang, O. Sansom, P. Adams (2011)
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.Molecular cell, 42 1
Z. Xu-Monette, L. Medeiros, Yong Li, Robert Orlowski, M. Andreeff, C. Bueso-Ramos, Timothy Greiner, Timothy McDonnell, Ken Young (2012)
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.Blood, 119 16
Jan Riggelen, Alper Yetil, D. Felsher (2010)
MYC as a regulator of ribosome biogenesis and protein synthesisNature Reviews Cancer, 10
E. Komarova, M. Chernov, R. Franks, Kaihua Wang, G. Armin, C. Zelnick, D. Chin, S. Bacus, G. Stark, A. Gudkov (1997)
Transgenic mice with p53‐responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivoThe EMBO Journal, 16
H. Wendel, E. Stanchina, J. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, S. Lowe (2004)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature, 428
W. Mondesire, W. Jian, Haixia Zhang, J. Ensor, M. Hung, G. Mills, F. Meric-Bernstam (2004)
Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer CellsClinical Cancer Research, 10
C. Nesbit, J. Tersak, E. Prochownik (1999)
MYC oncogenes and human neoplastic diseaseOncogene, 18
R. Hardy, C. Carmack, S. Shinton, J. Kemp, K. Hayakawa (1991)
Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrowThe Journal of Experimental Medicine, 173
Catherine Seager, Anna Puzio-Kuter, T. Patel, Shalini Jain, C. Cordon-Cardo, James Kiernan, C. Abate-Shen (2009)
Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder CancerCancer Prevention Research, 2
A. Wiegmans, A. Alsop, M. Bots, L. Cluse, Steven Williams, K. Banks, R. Ralli, C. Scott, A. Frenzel, A. Villunger, R. Johnstone (2011)
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.Cancer research, 71 10
K. Jacobsen, V. Prasad, C. Sidman, D. Osmond (1994)
Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice.Blood, 84 8
R. Lindemann, A. Newbold, K. Whitecross, L. Cluse, A. Frew, L. Ellis, Steven Williams, A. Wiegmans, A. Dear, C. Scott, M. Pellegrini, Andrew Wei, V. Richon, P. Marks, S. Lowe, M. Smyth, R. Johnstone (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaProceedings of the National Academy of Sciences, 104
M. Reimann, Soyoung Lee, C. Loddenkemper, J. Dörr, V. Tabor, P. Aichele, H. Stein, B. Dörken, T. Jenuwein, C. Schmitt (2010)
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.Cancer cell, 17 3
C. Eischen, J. Weber, M. Roussel, C. Sherr, J. Cleveland (1999)
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.Genes & development, 13 20
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, F. Group (2008)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 372
W. Xue, L. Zender, C. Miething, R. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, S. Lowe (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 445
C. Dang, A. Le, P. Gao (2009)
MYC-Induced Cancer Cell Energy Metabolism and Therapeutic OpportunitiesClinical Cancer Research, 15
M. Vita, M. Henriksson (2006)
The Myc oncoprotein as a therapeutic target for human cancer.Seminars in cancer biology, 16 4
D. Xing, S. Orsulic (2005)
A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.Proceedings of the National Academy of Sciences of the United States of America, 102 19
Jan Riggelen, Judith Müller, T. Otto, Vincent Beuger, Alper Yetil, P. Choi, C. Kosan, T. Möröy, D. Felsher, M. Eilers (2010)
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.Genes & development, 24 12
K. Livak, Thomas Schmittgen (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods, 25 4
A. Strasser, A. Harris, M. Bath, S. Cory (1990)
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2Nature, 348
S. Campaner, M. Doni, P. Hydbring, A. Verrecchia, L. Bianchi, D. Sardella, Thomas Schleker, D. Perna, Susanna Tronnersjö, M. Murga, O. Fernandez-Capetillo, M. Barbacid, L. Larsson, B. Amati (2010)
Cdk2 suppresses cellular senescence induced by the c-myc oncogeneNature Cell Biology, 12
M. Bywater, G. Poortinga, E. Sanij, Nadine Hein, Abigail Peck, C. Cullinane, Meaghan Wall, L. Cluse, D. Drygin, K. Anderes, N. Huser, C. Proffitt, J. Bliesath, M. Haddach, M. Schwaebe, D. Ryckman, W. Rice, C. Schmitt, S. Lowe, R. Johnstone, R. Pearson, G. McArthur, R. Hannan (2012)
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.Cancer cell, 22 1
M. Barna, A. Pusic, O. Zollo, M. Costa, Nadya Kondrashov, E. Rego, P. Rao, D. Ruggero (2008)
Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiencyNature, 456
M. Narita, S. Nũnez, E. Heard, M. Narita, Athena Lin, Stephen Hearn, D. Spector, G. Hannon, S. Lowe (2003)
Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular SenescenceCell, 113
Meaghan Wall, G. Poortinga, K. Hannan, R. Pearson, R. Hannan, G. McArthur (2008)
Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation.Blood, 112 6
A. Harris, Carl Pinkert, Marjorie Crawford, Wallace Langdon, Ralph Brinster, J. Adams (1988)
The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cellsThe Journal of Experimental Medicine, 167
K. Rakhra, P. Bachireddy, Tahera Zabuawala, R. Zeiser, Liwen Xu, Andrew Kopelman, A. Fan, Qiwei Yang, L. Braunstein, Erika Crosby, S. Ryeom, D. Felsher (2010)
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.Cancer cell, 18 5
J. Mills, Y. Hippo, F. Robert, Samuel Chen, A. Malina, Chen-ju Lin, U. Trojahn, H. Wendel, A. Charest, R. Bronson, S. Kogan, R. Nadon, D. Housman, S. Lowe, J. Pelletier (2008)
mTORC1 promotes survival through translational control of Mcl-1Proceedings of the National Academy of Sciences, 105
S. Mabuchi, D. Altomare, D. Connolly, Andres Klein-Szanto, S. Litwin, M. Hoelzle, H. Hensley, T. Hamilton, J. Testa (2007)
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.Cancer research, 67 6
W. Langdon, A. Harris, S. Cory, Jerry Adams (1986)
The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic miceCell, 47
T. Kuilman, C. Michaloglou, W. Mooi, D. Peeper (2010)
The essence of senescence.Genes & development, 24 22
Adam Freund, C. Patil, J. Campisi (2011)
p38MAPK is a novel DNA damage response‐independent regulator of the senescence‐associated secretory phenotypeThe EMBO Journal, 30
V. Anisimov, M. Zabezhinski, I. Popovich, T. Piskunova, A. Semenchenko, M. Tyndyk, M. Yurova, M. Antoch, M. Blagosklonny (2010)
Rapamycin extends maximal lifespan in cancer-prone mice.The American journal of pathology, 176 5
Shomit Sengupta, Timothy Peterson, D. Sabatini (2010)
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.Molecular cell, 40 2
L. Štefančíková, M. Moulis, P. Fabián, B. Ravčuková, I. Vášová, J. Mužík, J. Malcikova, I. Falková, Jana Slováčková, J. Šmardová (2010)
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.International journal of oncology, 36 3
A. Raimondi, A. Molinolo, J. Gutkind (2009)
Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.Cancer research, 69 10
Jerry Adams, A. Harris, C. Pinkert, L. Corcoran, W. Alexander, S. Cory, R. Palmiter, R. Brinster (1985)
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 318
M. Hemann, A. Bric, J. Teruya-Feldstein, A. Herbst, J. Nilsson, C. Cordon-Cardo, J. Cleveland, W. Tansey, S. Lowe (2005)
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsNature, 436
H. Wendel, A. Malina, Zhen Zhao, L. Zender, S. Kogan, C. Cordon-Cardo, J. Pelletier, S. Lowe (2006)
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.Cancer research, 66 15
P. Majumder, P. Febbo, Rachel Bikoff, R. Berger, Q. Xue, Louis McMahon, J. Manola, J. Brugarolas, T. McDonnell, T. Golub, M. Loda, H. Lane, W. Sellers (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNature Medicine, 10
B. Iritani, R. Eisenman (1999)
c-Myc enhances protein synthesis and cell size during B lymphocyte development.Proceedings of the National Academy of Sciences of the United States of America, 96 23
Liesbeth Vredeveld, P. Possik, Marjon Smit, Katrin Meissl, C. Michaloglou, H. Horlings, A. Ajouaou, P. Kortman, D. Dankort, M. McMahon, W. Mooi, D. Peeper (2012)
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Genes & development, 26 10
J. Gera, I. Mellinghoff, Yijiang Shi, M. Rettig, C. Tran, J. Hsu, C. Sawyers, A. Lichtenstein (2004)
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression*Journal of Biological Chemistry, 279
A. Egle, A. Harris, P. Bouillet, S. Cory (2004)
Bim is a suppressor of Myc-induced mouse B cell leukemia.Proceedings of the National Academy of Sciences of the United States of America, 101 16
D. Krueger, Marguerite Caré, Katherine Holland, K. Agricola, C. Tudor, P. Mangeshkar, Kimberly Wilson, A. Byars, T. Sahmoud, D. Franz (2010)
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.The New England journal of medicine, 363 19
J. Bain, Lorna Plater, M. Elliott, N. Shpiro, J. Hastie, Hilary, Mclauchlan, Iva Klevernic, Simon Arthur, D. Alessi, P. Cohen (2007)
The selectivity of protein kinase inhibitors: a further update.The Biochemical journal, 408 3
Huajun Yan, P. Frost, Yijiang Shi, B. Hoang, Sanjai Sharma, M. Fisher, J. Gera, A. Lichtenstein (2006)
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.Cancer research, 66 4
S. Lowe, H. Ruley, T. Jacks, D. Housman (1993)
p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 74
M. Ravitz, Li Chen, M. Lynch, E. Schmidt (2007)
c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.Cancer research, 67 23
R. Crazzolara, A. Cisterne, M. Thien, J. Hewson, Rana Baraz, K. Bradstock, L. Bendall (2009)
Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.Blood, 113 14
S. Mabuchi, D. Altomare, M. Cheung, Lili Zhang, Poulikos Poulikakos, H. Hensley, R. Schilder, R. Ozols, J. Testa (2007)
RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer ModelClinical Cancer Research, 13
Iwan Beuvink, A. Boulay, S. Fumagalli, Frédéric Zilbermann, S. Ruetz, T. O'reilly, F. Natt, Jonathan Hall, H. Lane, G. Thomas (2005)
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 120
C. Robledo, J. García, D. Caballero, E. Conde, R. Arranz, T. Flores, C. Grande, José Rodríguez, Eva Garcia, A. Sáez, Marcos González, N. Gutiérrez, M. Piris, J. Hernández (2009)
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B‐cell lymphomasCancer, 115
Cancer Discovery – Unpaywall
Published: Dec 16, 2012
Access the full text.
Sign up today, get DeepDyve free for 14 days.